

Obtaining Tecovirimat for hMPXV Patients  
Interim Guidance, Jul. 27, 2022

Dear Colleagues,

The antiviral [tecovirimat](#) is available under an investigational new drug (IND) protocol and may be considered for individuals with hMPXV meeting CDC-listed clinical criteria available at:

[www.cdc.gov/poxvirus/monkeypox/clinicians/Tecovirimat.html#anchor\\_1654624161405](http://www.cdc.gov/poxvirus/monkeypox/clinicians/Tecovirimat.html#anchor_1654624161405)

Clinical consultation from the CDC Pox Team is available through the CDC Emergency Operations Center at 770-488-7100.

Providers who identify patients with indications for tecovirimat can request it through OHA by completing the smart access form, available at: <https://app.smartsheet.com/b/form/8145964e7cf94d0bbe5754e83d3abde4> to obtain therapy.

Because tecovirimat is under an Investigational New Drug protocol, certain documentation is required. CDC is attempting to streamline this process. The protocol, explanation of current documentation requirements, and links to the relevant documents are available at:

[www.cdc.gov/poxvirus/monkeypox/clinicians/obtaining-tecovirimat.html?ACSTrackingID=CDC\\_1052-DM86266&ACSTrackingLabel=COCA%20Now%3A%20%20New%20Streamlined%20Process%20to%20Provide%20Tecovirimat%20\(TPOXX\)%20for%20Treatment%20of%20Monkeypox&deliveryName=CDC\\_1052-DM86266](http://www.cdc.gov/poxvirus/monkeypox/clinicians/obtaining-tecovirimat.html?ACSTrackingID=CDC_1052-DM86266&ACSTrackingLabel=COCA%20Now%3A%20%20New%20Streamlined%20Process%20to%20Provide%20Tecovirimat%20(TPOXX)%20for%20Treatment%20of%20Monkeypox&deliveryName=CDC_1052-DM86266)

Please return completed IND protocol forms to CDC by:

- Secure Share File for lesion photos and large file sizes: <https://centersfordiseasecontrol.sharefile.com/r-r3941801ebcbd4002b4dfe98e314ec697>
- Email: [regaffairs@cdc.gov](mailto:regaffairs@cdc.gov)
- Fax: 404-902-5921